WIRED reported on October 21, 2026, that OpenAI’s venture capital arm and Founders Fund were investing in Coherence Neuro’s $45 million seed round. The San Francisco startup is developing an experimental brain implant and AI models aimed at decoding electrical signals associated with brain tumors.
What Coherence Neuro is developing
Coherence Neuro says animal research has identified electrical signals associated with tumors growing, shrinking or recurring. Its implant is designed to record those signals and deliver mild electrical stimulation intended to halt tumor growth.
During summer 2026, the implant was placed for roughly 30 minutes in each of three people already undergoing brain-tumor removal surgery at Royal Melbourne Hospital in Melbourne, Australia. The procedure was an initial recording test and safety check.
By the time WIRED published its report, Coherence was testing recording and stimulation in seven additional patients. These were separate stages of research: the three-person procedure was brief, while the seven-patient testing involved both recording and stimulation.
The glioblastoma study was a planned next stage
Coherence Neuro planned to use the funding to launch a longer-term implant trial in patients with glioblastoma. WIRED’s October 21 report described the trial as planned.
What Coherence’s CEO said about data access
Coherence Neuro CEO and cofounder Ben Woodington said OpenAI would not have access to brain or other health data generated by the company.
